期刊
CHINESE JOURNAL OF CANCER RESEARCH
卷 35, 期 2, 页码 191-196出版社
CHINESE JOURNAL CANCER RESEARCH CO
DOI: 10.21147/j.issn.1000-9604.2023.02.08
关键词
Breast neoplasms; surveys and questionnaires; chemotherapy; adjuvant; practice patterns; physicians
类别
A cross-sectional online survey found that a high proportion of Chinese breast cancer physicians are willing to prescribe extended adjuvant endocrine therapy with aromatase inhibitors for more than 5 years, especially for postmenopausal females with higher risk. Doctors with more than 15 years of clinical experience are more likely to prescribe a longer duration of AET for low-risk patients. Half of the doctors consider intermittent letrozole as an acceptable option. Most doctors would prescribe adjuvant chemotherapy to genomic high-intermediate risk females aged <= 50 years regardless of the clinical risk classification.
A cross-sectional online survey was conducted. A high proportion of the Chinese breast cancer (BC) physician respondents (n=77) would prescribe extended adjuvant endocrine therapy (AET) with aromatase inhibitors (AI) beyond 5 years for postmenopausal females with BC, especially those with higher risk. Respondents with >= 15 years of clinical experience were more likely to prescribe a longer duration of AET for low-risk patients. Half of the respondents considered intermittent letrozole as an acceptable option. Most respondents would prescribe adjuvant chemotherapy to genomic high-intermediate risk [Oncotype DX recurrence score (RS) 21-25] females aged <= 50 years regardless of the clinical risk classification.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据